Jennifer R. Brown, MD, PhD: The Changing Definition of “High-Risk” CLL American Society of Hematology 5:09 8 years ago 1 765 Далее Скачать
Genomic evolution and resistance to pirtobrutinib in CLL: insights from the BRUIN study VJHemOnc – Video Journal of Hematology & HemOnc 2:20 1 year ago 356 Далее Скачать
Sequencing of BTK inhibitors in CLL VJHemOnc – Video Journal of Hematology & HemOnc 1:24 11 months ago 192 Далее Скачать
How genomic testing is used in the prognostication and diagnosis of patients with CLL VJHemOnc – Video Journal of Hematology & HemOnc 1:57 1 year ago 271 Далее Скачать
Jennifer Brown, MD, PhD, offers opinion on how zanubrutinib fits into the CLL treatment landscape OBRoncology 1:17 3 years ago 137 Далее Скачать
Dr. Jennifer Brown on Ibrutinib, Idelalisib, and Other Agents for CLL OncLive 1:24 11 years ago 1 494 Далее Скачать
ASH Impact Series: Jennifer Brown, MD, PhD - Treating High-Risk CLL American Society of Hematology 4:24 7 years ago 757 Далее Скачать
Jennifer Brown, MD, PhD, Discusses Genomic Evolution of Pirtobrutinib Resistance Blood Cancers Today 3:13 1 year ago 117 Далее Скачать
CLL at a genomic level VJHemOnc – Video Journal of Hematology & HemOnc 2:13 3 years ago 83 Далее Скачать
Dr. Jennifer Brown on CLL Mutations, Pathways, and Targets Targeted Oncology 0:52 11 years ago 94 Далее Скачать
Challenges in interpreting the results of genomic tests in CLL VJHemOnc – Video Journal of Hematology & HemOnc 1:33 1 year ago 60 Далее Скачать
